Aducanumab, an antibody developed by the University of Zurich, has been shown to trigger a meaningful reduction of harmful beta-amyloid plaques in patients with early-stage Alzheimer’s disease.
These protein deposits in the brain are a classic sign of Alzheimer’s disease and contribute to the progressive degeneration of brain cells. The researchers furthermore demonstrated in an early stage clinical study that, after one year of treatment with Aducanumab, cognitive decline could be significantly slowed in antibody-treated patients as opposed to the placebo group.
Although the causes of Alzheimer’s disease are still unknown, it is clear that the disease commences with progressive amyloid deposition in the brains of affected persons between ten and fifteen years before the emergence of initial clinical symptoms such as memory loss. Researchers have now been able to show that Aducanumab, a human monoclonal antibody, selectively binds brain amyloid plaques, thus enabling microglial cells to remove the plaques. A one-year treatment with the antibody, as part of a phase Ib study, resulted in almost complete clearance of the brain amyloid plaques in the study group patients. The results, which were realized by researchers at UZH together with the biotech company “Biogen” and the UZH spin-off “Neurimmune,” have been published in the renowned science journal “Nature.”
Reduction of brain amyloid plaque is dependent on treatment duration and dosage
“The results of this clinical study make us optimistic that we can potentially make a great step forward in treating Alzheimer’s disease,” says Roger M. Nitsch, professor at the Institute for Regenerative Medicine at UZH. “The effect of the antibody is very impressive. And the outcome is dependent on the dosage and length of treatment.” After one year of treatment, practically no beta-amyloid plaques could be detected in the patients who received the highest dose of the antibody.
The antibody was developed with the help of a technology platform from “Neurimmune.” Using blood collected from elderly persons aged up to one hundred and demonstrating no cognitive impairment, the researchers isolated precisely those immune cells whose antibodies are able to identify toxic beta-amyloid plaques but not the amyloid precursor protein that is present throughout the human body and that presumably plays an important role in the growth of nerve cells. The good safety profile of Aducanumab in patients may well be attributed to the antibody’s specific capacity to bond with the abnormally folded beta-amyloid protein fragment as well as the fact that the antibody is of human origin.
Investigational treatment also curbs cognitive decline
165 patients with early-stage Alzheimer’s disease were treated in the phase 1b clinical trial. Although not initially planned as a primary study objective, the good results encouraged researchers to additionally investigate how the treatment affected the symptoms of disease. This was evaluated via standardized questionnaires to assess the cognitive abilities and everyday activities of the patients. “Aducanumab also showed positive effects on clinical symptoms,” is how Nitsch sums up the findings. “While patients in the placebo group exhibited significant cognitive decline, cognitive ability remained distinctly more stable in patients receiving the antibody.”
Some of the trial participants temporarily suffered from amyloid-related imaging abnormality (ARIA), an adverse effect that can be detected via magnetic resonance imaging. In a minority of cases, this was accompanied by temporary mild to moderate headaches. The UZH researchers believe that ARIA is a measurable biological effect of amyloid clearance.
The promising effects of Aducanumab are currently being investigated in two large phase three clinical studies to further evaluate safety and efficacy. Involving over 300 centers in 20 countries throughout North America, Europe, and Asia, these studies are evaluating the effectiveness and safety of the antibody on a total of 2,700 patients with early-stage Alzheimer’s disease.
The Latest on: Aducanumab
via Google News
The Latest on: Aducanumab
- Court Appoints Lead Plaintiff, Denies Appointment of Lead Counsel in Biogen Securities Suiton March 3, 2021 at 12:18 am
Law Street provides accessible, client-focused legal news designed to inform readers and connect lawyers with the legal needs in their field.
- Alzheimer’s Disease: From Diagnosis to Treatment, Change Is Comingon March 1, 2021 at 1:32 am
Recent Alzheimer’s disease research has poised the field for a watershed period in diagnosis and treatment, which may begin as early as this year. This shifting clinical landscape in Alzheimer’s ...
- Regulation - Drug Trial, US FDA, aducanumabon February 25, 2021 at 4:00 pm
The US regulator has accepted for Priority Review a submission to broaden the label for Jakafi (ruxolitinib),… Hopes that BrainStorm Cell Therapeutics could deliver a new option in amyotrophic lateral ...
- Would ApoE Make a Better Therapeutic Target Than Aβ?on February 25, 2021 at 4:00 pm
Anti-ApoE antibody HAE-4 clears plaque from a mouse model better than aducanumab did. Unlike aducanumab, HAE-4 causes no microhemorrhages. HAE-4 preferentially triggers microglia over astrocytes, and ...
- BOOKS: New book chronicles four-decade fight against Alzheimer'son February 24, 2021 at 8:00 pm
Possibly the first drug to effectively stay the progression of Alzheimer's disease, the market saw the FDA delay as a positive sign that world's peak drug regulatory agency was leaning toward approval ...
- Biogen And The Politics Of Alzheimer's Diseaseon February 23, 2021 at 5:30 am
Aducanumab may substantially slow down Alzheimer's disease in individuals with two copies of the ApoE4 gene, but only closer to the rate of decline experienced by non-carriers. Those with two copies ...
- 1. Aducanumabon February 22, 2021 at 1:28 am
No other pending drug approval faces more skepticism on one hand, and more cheerleading on the other, than Biogen’s anti-amyloid beta antibody aducanumab for Alzheimer’s disease. On one side ...
- Biogen: High On Hopeon February 18, 2021 at 3:23 am
Biogen’s share price is flotsam ebbing and flowing with the perceived fortunes of aducanumab as it works its way through the FDA. Biogen (BIIB) has been caught in a bit of a rut as its top ...
- A safer Alzheimer's drug than Biogen's aducanumab? Denali-WashU drug shows better profile in miceon February 18, 2021 at 12:24 am
Now, the team has returned with mouse data suggesting the drug prospect might be a safer option than Biogen’s much-hyped aducanumab. The antibody, called HAE-4, targets the APOE4 gene ...
via Bing News